Is MCF-7 luminal A or B?

Is MCF-7 luminal A or B?

It is ER-positive and progesterone receptor (PR)-positive (8) and belongs to the luminal A molecular subtype (2). MCF-7 is a poorly-aggressive and non-invasive cell line (9), normally being considered to have low metastatic potential (8).

What is MCF-7 cell line?

MCF-7 is a human breast cancer cell line with estrogen, progesterone and glucocorticoid receptors [26]. It is derived from the pleural effusion of a 69-year-old Caucasian metastatic breast cancer (adenocarcinoma) in 1970 by Dr Soule of the Michigan Cancer Foundation, Detroit, MI [27].

Is MCF-7 invasive?

Though MCF7 is categorized as poorly invasive, its migration in the 2D surface is found to be comparable to the highly invasive MDA MB 231 in the current study.

Is MCF-7 a gene?

In microarray profiles, the MCF-7 gene set clusters with the luminal subtype of breast cancer. MCF-7 xenografts express wild-type p53 and are nonmetastatic even when implanted orthotopically into the mammary fat pad.

Which MDA-MB-453 cells have low levels of ER-beta?

While T47DCo (a T47D variant cell line), BT474, MDA-MB-231, MDA-MB-453, MDA-MB-468 and MCF-7 express low levels of ER-beta, other cell lines including the T47D-Y (a T47D variant cell line), MDA-MB-435, BT-549, and SKBr-3 cells express undetectable levels of ER-beta.

Is estradiol up-regulation of ER-beta a prognostic marker for breast cancer?

Moreover, the studies demonstrate that estradiol up-regulation of ER-beta mRNA in T47D cells can be abolished by anti-estrogens. Thus, ER-beta expression may serve as a prognostic, diagnostic and/or therapeutic marker for breast cancer.

Which estrogen receptor variant lacking exon 5 has dominant negative activity?

The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1. Cancer Res. 1998;58:4264–4268. [PubMed] [Google Scholar]

Does doxorubicin interact with estrogen receptors in triple negative breast cancer?

Elevated estrogen receptor β expression in triple negative breast cancer cells is associated with sensitivity to doxorubicin by inhibiting the PI3K/AKT/mTOR signaling pathway Based on its pathological characteristics, breast cancer is a highly heterogeneous disease.